GLI3R is required for the therapeutic effect of SMO antagonists in AML samples [109].Component of the Hedgehog signaling pathway, which is implicated in the development, maintenance, and expansion of leukemic stem cells (LSC) chemosensitivity and drug resistance [110]. Here, SMO is linked to acute myeloid leukemia.